Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Kaleido Biosciences CEO Alison Lawton to step down » 16:46
06/16/20
06/16
16:46
06/16/20
16:46
KLDO

Kaleido Biosciences

$7.52 /

+0.22 (+3.01%)

Kaleido Biosciences…

Kaleido Biosciences announced that Alison Lawton has chosen to step down from her position as President and CEO in order to return to the United Kingdom and attend to an unexpected family health matter. Lawton will continue to serve as a Director and special advisor to Kaleido and will support the company through this transition. Kaleido's Board of Directors will be initiating a search for a new CEO and has established an Office of the CEO to lead the organization and to advance its strategic goals during this transition period. The Office of the CEO will be comprised of Mike Bonney and Lawton. Bonney is the Executive Chair and former CEO of Kaleido and has more than 25 years of experience leading biotechnology and pharmaceutical companies, including 12 years as the CEO of Cubist Pharmaceuticals. Other members of the Board of Directors have also committed to providing their expertise and support to the organization until a successor CEO is identified.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$7.52 /

+0.22 (+3.01%)

KLDO Kaleido Biosciences
$7.52 /

+0.22 (+3.01%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs
05/21/20 Morgan Stanley
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley
KLDO Kaleido Biosciences
$7.52 /

+0.22 (+3.01%)

KLDO Kaleido Biosciences
$7.52 /

+0.22 (+3.01%)

Conference/Events
Goldman Sachs to hold a virtual conference » 08:47
06/11/20
06/11
08:47
06/11/20
08:47
HUM

Humana

$392.51 /

+1.51 (+0.39%)

, DTIL

Precision BioSciences

$8.30 /

-0.31 (-3.60%)

, CHNG

Change Healthcare

$11.85 /

-0.37 (-3.03%)

, ALKS

Alkermes

$16.77 /

-0.51 (-2.95%)

, ALNY

Alnylam

$129.96 /

+0.09 (+0.07%)

, HCAT

Health Catalyst

$28.79 /

+0.1 (+0.35%)

, KLDO

Kaleido Biosciences

$7.44 /

-0.155 (-2.04%)

, ZEAL

Zealand Pharma

$39.08 /

+0.48 (+1.24%)

, GOSS

Gossamer Bio

$12.38 /

-0.23 (-1.82%)

, MRNA

Moderna

$59.88 /

+1.58 (+2.71%)

, ORTX

Orchard Therapeutics

$7.99 /

+0.23 (+2.96%)

, BMY

Bristol-Myers

$60.15 /

-0.75 (-1.23%)

, ADVM

Adverum Biotechnologies

$23.85 /

+0.44 (+1.88%)

, BCYC

Bicycle Therapeutics

$17.35 /

+0.15 (+0.87%)

, ESPR

Esperion

$46.64 /

-1.01 (-2.12%)

, PHAT

Phathom Pharmaceuticals

$50.33 /

-1.45 (-2.80%)

, INSP

Inspire Medical

$85.53 /

-3.11 (-3.51%)

, UBX

Unity Biotechnology

$8.88 /

+0.32 (+3.74%)

, PHG

Philips

$46.76 /

-0.39 (-0.83%)

, ATRA

Atara Biotherapeutics

$9.91 /

-0.455 (-4.39%)

41st Annual Global…

41st Annual Global Healthcare Virtual Conference will be held on June 9-11. Webcast Link

ShowHide Related Items >><<
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

06/05/20 Goldman Sachs
Humana initiated with a Buy at Goldman Sachs
06/01/20 Stephens
Molina Healthcare price target raised to $215 from $202 at Stephens
05/21/20 SunTrust
SunTrust raises price targets across select Healthcare Services names
05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

06/10/20 KeyBanc
Inovalon displaces Change Healthcare in Priority Health deal, says KeyBanc
06/09/20 Piper Sandler
Piper Sandler says buy Change Healthcare, sell Inovalon
04/13/20 SVB Leerink
Change Healthcare initiated with an Outperform at SVB Leerink
03/26/20 Cowen
Cowen sees three healthcare IT names poised for rebound
ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

04/30/20 H.C. Wainwright
Alkermes price target lowered to $23 from $25 at H.C. Wainwright
04/29/20 Piper Sandler
Alkermes price target lowered to $21 from $22 at Piper Sandler
04/29/20 Stifel
Alkermes price target lowered to $17 from $20 at Stifel
02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

05/27/20 Piper Sandler
Piper bullish on post pandemic opportunities for Health Catalyst
05/15/20
Fly Intel: Top five analyst initiations
05/15/20 Guggenheim
Guggenheim sees Health Catalyst at attractive entry point, starts at Buy
05/15/20 Guggenheim
Health Catalyst initiated with a Buy at Guggenheim
KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs
05/21/20 Morgan Stanley
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

03/10/20 Morgan Stanley
Zealand Pharma EPS estimates cut at Morgan Stanley
11/19/19 Jefferies
Zealand Pharma downgraded to Hold from Buy at Jefferies
11/15/19 Needham
Zealand Pharma price target raised to $42 from $32 at Needham
10/15/19
Fly Intel: Top five analyst upgrades
GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

05/29/20 Piper Sandler
Piper says Gossamer's GB1275 well tolerated, early activity signs 'promising'
05/20/20 SVB Leerink
Gossamer Bio price target raised to $36 from $27 at SVB Leerink
04/22/20 Piper Sandler
Gossamer Bio initiated with an Overweight at Piper Sandler
02/27/20 Barclays
Gossamer Bio initiated with an Overweight at Barclays
MRNA Moderna
$59.88 /

+1.58 (+2.71%)

06/08/20 Barclays
Moderna initiated with an Overweight at Barclays
06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
06/02/20 BofA
Moderna price target lowered to $75 from $80 at BofA
06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

05/22/20 JPMorgan
Orchard Therapeutics price target lowered to $17 from $26 at JPMorgan
09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

05/29/20 Piper Sandler
Adverum Biotechnologies price target raised to $25 from $20 at Piper Sandler
05/12/20 RBC Capital
Adverum Biotechnologies initiated with an Outperform at RBC Capital
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
ESPR Esperion
$46.64 /

-1.01 (-2.12%)

05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
04/20/20 JMP Securities
JMP reiterates $191 price target on Esperion after Japan partnership
04/16/20 Northland
Esperion price target lowered to $42 from $60 at Northland
04/01/20
Fly Intel: Top five analyst initiations
PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

11/19/19 Evercore ISI
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/19/19 Jefferies
Phathom Pharmaceuticals initiated with a Buy at Jefferies
INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

05/26/20 Wells Fargo
Inspire Medical price target raised to $95 from $81 at Wells Fargo
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Lake Street
Inspire Medical initiated with a Buy at Lake Street
05/06/20 Guggenheim
Inspire Medical price target raised to $90 from $80 at Guggenheim
UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
PHG Philips
$46.76 /

-0.39 (-0.83%)

04/22/20 Morgan Stanley
Philips price target lowered to EUR 45 from EUR 50 at Morgan Stanley
04/21/20 JPMorgan
Philips price target raised to EUR 36.80 from EUR 33.90 at JPMorgan
04/07/20 JPMorgan
Philips price target lowered to EUR 33.90 from EUR 43.10 at JPMorgan
03/24/20 DZ Bank
Philips upgraded to Buy from Hold at DZ Bank
ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

05/22/20 Mizuho
Atara multiple sclerosis data looks 'awesome' at first glance, says Mizuho
04/23/20 Citi
Atara Biotherapeutics upgraded to Buy on valuation at Citi
04/23/20 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

On The Fly
Fly Insider: Danaher, AMD among week's notable insider transactions » 13:29
06/08/20
06/08
13:29
06/08/20
13:29
NKLA

Nikola

$56.68 /

+20.76 (+57.80%)

, CBAT

CBAK Energy Technology

$0.75 /

+0.2036 (+37.33%)

, KLDO

Kaleido Biosciences

$7.33 /

+0.26 (+3.68%)

, LJPC

La Jolla

$5.61 /

+0.21 (+3.89%)

, DHR

Danaher

$172.28 /

-0.97 (-0.56%)

, ACMR

ACM Research

$56.76 /

-5.55 (-8.91%)

, AMD

AMD

$52.57 /

-0.54 (-1.02%)

, APO

Apollo Global

$52.45 /

-0.72 (-1.35%)

, BLL

Ball Corp.

$72.95 /

-0.95 (-1.29%)

, ANGI

Angi Homeservices

$12.13 /

-0.45 (-3.58%)

Welcome to "Fly Insider,"…

Open Full Text

ShowHide Related Items >><<
NKLA Nikola
$56.68 /

+20.76 (+57.80%)

LJPC La Jolla
$5.61 /

+0.21 (+3.89%)

KLDO Kaleido Biosciences
$7.33 /

+0.26 (+3.68%)

DHR Danaher
$172.28 /

-0.97 (-0.56%)

CBAT CBAK Energy Technology
$0.75 /

+0.2036 (+37.33%)

BLL Ball Corp.
$72.95 /

-0.95 (-1.29%)

APO Apollo Global
$52.45 /

-0.72 (-1.35%)

ANGI Angi Homeservices
$12.13 /

-0.45 (-3.58%)

AMD AMD
$52.57 /

-0.54 (-1.02%)

ACMR ACM Research
$56.76 /

-5.55 (-8.91%)

NKLA Nikola
$56.68 /

+20.76 (+57.80%)

CBAT CBAK Energy Technology
$0.75 /

+0.2036 (+37.33%)

KLDO Kaleido Biosciences
$7.33 /

+0.26 (+3.68%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs
05/21/20 Morgan Stanley
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley
LJPC La Jolla
$5.61 /

+0.21 (+3.89%)

05/07/20 Gabelli
Tetraphase upgraded to Hold from Sell at Gabelli
01/09/20 H.C. Wainwright
H.C. Wainwright still sees 2020 sales of La Jolla's Giaprezza as immaterial
11/26/19 H.C. Wainwright
La Jolla downgraded to Neutral from Buy at H.C. Wainwright
11/26/19 Nomura Instinet
La Jolla failure a positive for Protagonist Therapeutics, says Nomura Instinet
DHR Danaher
$172.28 /

-0.97 (-0.56%)

05/11/20 RBC Capital
Danaher price target raised to $173 from $159 at RBC Capital
04/21/20 Wells Fargo
Danaher price target raised to $170 from $155 at Wells Fargo
04/02/20 Wolfe Research
Danaher downgraded to Peer Perform from Outperform at Wolfe Research
03/30/20 Wells Fargo
Danaher price target lowered to $155 from $176 at Wells Fargo
ACMR ACM Research
$56.76 /

-5.55 (-8.91%)

05/19/20 Roth Capital
ACM Research price target raised to $80 from $60 at Roth Capital
05/07/20 Stifel
ACM Research price target raised to $50 from $28 at Stifel
04/15/20 Roth Capital
ACM Research price target raised to $50 from $32 at Roth Capital
01/22/20
Fly Intel: Top five analyst initiations
AMD AMD
$52.57 /

-0.54 (-1.02%)

06/02/20 Nomura Instinet
Nomura stays selective in Semis, keeps Buys on AMD and Intel
06/01/20 Northland
Northland sees strong second half ahead for AMD
05/15/20 Piper Sandler
Piper survey finds people are playing more video games during COVID-19
05/01/20 Loop Capital
AMD price target raised to $60 from $54 at Loop Capital
APO Apollo Global
$52.45 /

-0.72 (-1.35%)

06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
06/08/20 Citi
Apollo Global downgraded to Neutral from Buy at Citi
05/14/20 BMO Capital
Apollo Global downgraded to Market Perform on valuation at BMO Capital
05/14/20 BMO Capital
Apollo Global downgraded to Market Perform from Outperform at BMO Capital
BLL Ball Corp.
$72.95 /

-0.95 (-1.29%)

06/01/20 Atlantic Equities
Ball Corp. initiated with a Neutral at Atlantic Equities
05/08/20 Barclays
Ball Corp. price target lowered to $72 from $82 at Barclays
04/07/20 Goldman Sachs
Goldman cuts paper and packaging estimates, prefers Ball and Graphic Packaging
03/23/20 Goldman Sachs
Ball Corp, Crown Holdings upgraded to Buy at Goldman Sachs
ANGI Angi Homeservices
$12.13 /

-0.45 (-3.58%)

06/02/20 Deutsche Bank
Angi Homeservices price target raised to $12.50 from $10 at Deutsche Bank
05/11/20 Oppenheimer
IAC price target raised to $275 from $265 at Oppenheimer
05/11/20 Citi
Angi Homeservices price target raised to $10 from $6.50 at Citi
05/08/20 Barclays
IAC price target raised to $290 from $270 at Barclays
LJPC La Jolla
$5.61 /

+0.21 (+3.89%)

KLDO Kaleido Biosciences
$7.33 /

+0.26 (+3.68%)

DHR Danaher
$172.28 /

-0.97 (-0.56%)

BLL Ball Corp.
$72.95 /

-0.95 (-1.29%)

APO Apollo Global
$52.45 /

-0.72 (-1.35%)

ANGI Angi Homeservices
$12.13 /

-0.45 (-3.58%)

AMD AMD
$52.57 /

-0.54 (-1.02%)

ACMR ACM Research
$56.76 /

-5.55 (-8.91%)

APO Apollo Global
$52.45 /

-0.72 (-1.35%)

AMD AMD
$52.57 /

-0.54 (-1.02%)

LJPC La Jolla
$5.61 /

+0.21 (+3.89%)

DHR Danaher
$172.28 /

-0.97 (-0.56%)

APO Apollo Global
$52.45 /

-0.72 (-1.35%)

ANGI Angi Homeservices
$12.13 /

-0.45 (-3.58%)

AMD AMD
$52.57 /

-0.54 (-1.02%)

NKLA Nikola
$56.68 /

+20.76 (+57.80%)

DHR Danaher
$172.28 /

-0.97 (-0.56%)

BLL Ball Corp.
$72.95 /

-0.95 (-1.29%)

APO Apollo Global
$52.45 /

-0.72 (-1.35%)

ANGI Angi Homeservices
$12.13 /

-0.45 (-3.58%)

AMD AMD
$52.57 /

-0.54 (-1.02%)

ACMR ACM Research
$56.76 /

-5.55 (-8.91%)

Over a month ago
Syndicate
Kaleido Biosciences 4.75M share Spot Secondary priced at $7.50 » 06:14
06/02/20
06/02
06:14
06/02/20
06:14
KLDO

Kaleido Biosciences

$8.00 /

+0.75 (+10.34%)

Morgan Stanley acted as…

Morgan Stanley acted as lead book running manager for the offering.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$8.00 /

+0.75 (+10.34%)

KLDO Kaleido Biosciences
$8.00 /

+0.75 (+10.34%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs
05/21/20 Morgan Stanley
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley
KLDO Kaleido Biosciences
$8.00 /

+0.75 (+10.34%)

  • 02
    Jun
Syndicate
Kaleido Biosciences announces $30M common stock offering » 16:19
06/01/20
06/01
16:19
06/01/20
16:19
KLDO

Kaleido Biosciences

$8.00 /

+0.75 (+10.34%)

Kaleido Biosciences…

Kaleido Biosciences announced that it intends to sell, subject to market and other conditions, $30M of shares of its common stock in an underwritten public offering. Kaleido intends to use the net proceeds from the offering, in addition to its existing cash resources, to fund its continued research and development activities, including the ongoing clinical program of KB109 in patients with mild-to-moderate COVID-19, the ongoing Phase 2 clinical trial of KB195 in patients with urea cycle disorders, and the planned clinical study of KB295 in patients with mild-to-moderate ulcerative colitis, to fund any other research and development activities that relate to its current and future clinical and preclinical activities, and the remainder for planned general and administrative expenses, working capital and other general corporate purposes. Morgan Stanley is acting as sole book-running manager for the offering. Canaccord Genuity is acting as lead manager for the offering.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$8.00 /

+0.75 (+10.34%)

KLDO Kaleido Biosciences
$8.00 /

+0.75 (+10.34%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs
05/21/20 Morgan Stanley
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley
KLDO Kaleido Biosciences
$8.00 /

+0.75 (+10.34%)

Downgrade
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs » 07:53
05/21/20
05/21
07:53
05/21/20
07:53
KLDO

Kaleido Biosciences

$6.60 /

+0.01 (+0.15%)

As previously reported,…

As previously reported, Morgan Stanley analyst Matthew Harrison downgraded Kaleido Biosciences to Equal Weight from Overweight with a price target of $8, down from $15. Initial proof-of-concept data has been encouraging for Kaleido's MMT product candidates for hyperammonemia programs targeting urea cycle disorders and hepatic encephalopathy, but data from the Phase 2 program in UCD will be further delayed to the second half of 2021 due to the impact of COVID-19, Harrison tells investors. While an understandable consequence of COVID-19, he thinks its best to move to a lower rating pending greater certainty regarding a readout for KB195 in UCD and a more defined timeline towards data for KB174 in hyperammonemia, Harrison said.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$6.60 /

+0.01 (+0.15%)

KLDO Kaleido Biosciences
$6.60 /

+0.01 (+0.15%)

05/21/20 Morgan Stanley
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley
KLDO Kaleido Biosciences
$6.60 /

+0.01 (+0.15%)

Downgrade
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley » 05:20
05/21/20
05/21
05:20
05/21/20
05:20
KLDO

Kaleido Biosciences

$6.60 /

+0.01 (+0.15%)

Morgan Stanley analyst…

Morgan Stanley analyst Matthew Harrison downgraded Kaleido Biosciences to Equal Weight from Overweight with an $8 price target.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$6.60 /

+0.01 (+0.15%)

KLDO Kaleido Biosciences
$6.60 /

+0.01 (+0.15%)

Hot Stocks
Kaleido Biosciences begins clinical study of KB109 in COVID-19 patients » 06:39
05/14/20
05/14
06:39
05/14/20
06:39
KLDO

Kaleido Biosciences

$6.42 /

-0.28 (-4.18%)

Kaleido Biosciences…

Kaleido Biosciences initiated a controlled clinical study evaluating Microbiome Metabolic Therapy candidate KB109 added to Supportive Self-Care for outpatients who are positive for SARs-Cov-2 infection with mild-to-moderate COVID-19. "The burden of the COVID-19 pandemic on patients and healthcare facilities is vast, and there remains a need for interventional studies evaluating patients with mild-to-moderate disease, which represents the majority of infections," said Chief Medical Officer and Head of Research & Development Katharine Knobil. "We have evidence from our ex vivo research that KB109 increases the production of metabolites that have been shown to improve the immune response in viral respiratory infections. Published data suggest these metabolites may prevent an overaggressive immune response to COVID-19 and avoid more serious complications of this infection. Because of the favorable safety profile of KB109, we are able to rapidly initiate this very important clinical study. We look forward to exploring the potential of KB109 in COVID-19 as well as expanding our understanding of its applicability to other infections." The studies will include assessment of clinical outcomes, healthcare utilization, and biomarkers of the inflammatory response that will inform the potential of KB109 in COVID-19 as well as other viral and bacterial infections. Top-line data from the multi-center study are expected in Q4.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$6.42 /

-0.28 (-4.18%)

KLDO Kaleido Biosciences
$6.42 /

-0.28 (-4.18%)

Earnings
Kaleido Biosciences reports Q1 EPS (64c), consensus (64c) » 06:36
05/14/20
05/14
06:36
05/14/20
06:36
KLDO

Kaleido Biosciences

$6.42 /

-0.28 (-4.18%)

As of March 31, the…

As of March 31, the company reported cash and cash equivalents of $53.8M. Kaleido has extended its cash runway further into the first quarter of 2021.CEO Alison Lawton said, "We are fortunate that our product platform and efficient development model provide Kaleido flexibility in responding to the current situation. We have rapidly initiated new clinical programs aimed at addressing the unmet need for outpatients with mild-to-moderate COVID-19 disease and are further exploring the potential of MMTs in immune-mediated and inflammatory diseases in ulcerative colitis. We anticipate data readouts from these and other programs starting in Q4 2020 and throughout 2021". "

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$6.42 /

-0.28 (-4.18%)

KLDO Kaleido Biosciences
$6.42 /

-0.28 (-4.18%)

Over a quarter ago
Hot Stocks
Kaleido Biosciences appoints Anne Prener to board of directors » 08:39
04/03/20
04/03
08:39
04/03/20
08:39
KLDO

Kaleido Biosciences

$5.40 /

+0.155 (+2.96%)

Kaleido Biosciences…

Kaleido Biosciences announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors. Prener has more than 25 years of leadership experience within life sciences companies, and recently served as CEO of Freeline Ltd.

ShowHide Related Items >><<
KLDO Kaleido Biosciences
$5.40 /

+0.155 (+2.96%)

04/23/19 Chardan
Kaleido Biosciences initiated with a Buy at Chardan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.